April 25, 2018 / 12:10 PM / 3 months ago

BRIEF-AveXis Announces First Patient Dosed In Phase 3 Trial Of AVXS-101 In Pre-Symptomatic SMA Types 1, 2 And 3

April 25 (Reuters) - AveXis Inc:

* AVEXIS ANNOUNCES FIRST PATIENT DOSED IN PHASE 3 TRIAL OF AVXS-101 IN PRE-SYMPTOMATIC SMA TYPES 1, 2 AND 3 Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below